OTCMKTS:NRIFF Nuvo Pharmaceuticals (NRIFF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Nuvo Pharmaceuticals Stock (OTCMKTS:NRIFF) 30 days 90 days 365 days Advanced Chart Get Nuvo Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,000 shsAverage Volume7,337 shsMarket Capitalization$8.52 millionP/E Ratio18.69Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Read More… Receive NRIFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIFF Stock News Headlines4 Best Home Oxygen Concentrators Of 2024February 14, 2024 | forbes.comMiravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South KoreaJuly 29, 2021 | benzinga.comSee More Headlines NRIFF Stock Analysis - Frequently Asked Questions How do I buy shares of Nuvo Pharmaceuticals? Shares of NRIFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:NRIFF CIKN/A Webwww.nuvopharmaceuticals.com Phone(905) 673-6980FaxN/AEmployees99Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio18.69 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.53 million Net Margins-2.81% Pretax MarginN/A Return on Equity8.02% Return on Assets1.11% Debt Debt-to-Equity Ratio5.27 Current Ratio2.67 Quick Ratio2.11 Sales & Book Value Annual Sales$52.41 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.82 Book Value$1.59 per share Price / BookN/AMiscellaneous Outstanding Shares11,400,000Free FloatN/AMarket Cap$8.52 million OptionableNot Optionable Beta1.57 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:NRIFF) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvo Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.